ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2017 American Transplant Congress

April 29-May 3, 2017 in Chicago, IL

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Identification of a Stable Gene Signature of Transplant Tolerance to Liver Allograft by Meta-Analysis.

    G. Gu, H. Hang, Q. Xia.

  • Identification of Antibody-Mediated Rejection After Kidney Transplantation by Specific MicroRNAs.

    M. Matz,1 F. Heinrich,2 P. Durek,2 C. Lorkowski,1 K. Wu,3 N. Lachmann,4 K. Budde,1 M.-F. Mashreghi.2

  • Identification of Kidney Transplant Patients at Risk for Skin Cancer by Differentially Methylated Regions in T Cells.

    F. Peters,1 A. Peeters,1 P. Mandaviya,2 J. van de Wetering,1 M. Betjes,1 C. Baan,1 K. Boer.1

  • Identification of NKG2D as Senescence Marker in Zero-Hour Kidney Biopsies Is Indicative for Clinical Outcome.

    T. Resch,1 J. Günther,1 H. Hackl,2 A. Sattler,3 S. Ebner,1 P. Ritschl,3 M. Biebl,3 R. Öllinger,3 S. Schneeberger,1 G. Brandacher,4 H. Schwelberger,1 B. Zelger,5 D. Stauch,3 A. Pascher,3 J. Pratschke,3 K. Kotsch.3

  • Identification of Novel Diagnostic Biomarkers in Liver Transplantation Tolerance.

    G.-Q. Shen,1 M. Morita,1 C. Miller,1 K. Hashimoto,1 L. Lu,1 S. Qian,1 J. Fung.2

  • Identification of Plasma Protein Biomarkers of Acute Renal Allograft Rejection.

    M. Rossetti,1 C. Fitzpatrick,1 N. Harre,1 Y. Zheng,1 N. Mercer,2 G. Sunga,1 D. Gjertson,1 E. Reed.1

  • Identification of Promising Targets for Tolerance Induction Following Heart Transplantation.

    K. Klaeske, M.-T. Dieterlen, J. Fischer, J. Hahn, K. Jawad, J. Garbade, F. Mohr, S. Lehmann.

  • Identify Clinical and Masked Hypertension and Management Strategies in Pediatric Liver Transplant Patients.

    R. Hendrickson, M. Davis, A. Sherman, W. Andrews, J. Daniel, R. Fischer, D. Blowey.

  • Identifying Independent Risk Factors for Graft Loss After Primary Liver Transplantation: A Propensity Score Matched Analysis.

    J. Gwiasda, H. Schrem, A. Kaltenborn.

  • Identifying Risk of Sepsis Early: A Way to Improve Outcomes for Patients with Early Allograft Dysfunction After Liver Transplantation?

    D. Hoyer, T. Benko, G. Sotiropoulos, A. Paul, F. Saner.

  • Identifying Risks and Screening Deceased Organ Donors in the UK for Trypanosoma cruzi .

    I. Ushiro-Lumb,1,2 M. Webster,1 A. Kitchen.1

  • Identifying the Specific Causes and the Determinants of Outcome in Kidney Recipients with Transplant Glomerulopathy: A Multicenter Study.

    O. Aubert,1 S. Higgins,1 P. Campbell,2 C. Loheac,1 D. Viglietti,1 D. Glotz,1 C. Legendre,1 C. Lefaucheur,1 B. Sis,2 J. Duong Van Huyen,1 A. Loupy.1

  • IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-CMV IgG, Resulting in Inhibition of Antibody (Ab)-Mediated NK Cell Activation in Kidney Transplant Patients (KTX Pts).

    B.-H. Shin,1 S. Ge,1 M. Chu,1 J. Choi,1 L. Winstedt,2 C. Kjellman,2 S. Louie,1 A. Vo,1 A. Peng,1 S. Jordan,1 M. Toyoda.1

  • IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-HLA Antibody (Ab), Resulting in Inhibition of Anti-HLA Ab-Mediated NK Cell Activation and Ab-Dependent Cell-Mediated Cytotoxicity (ADCC) in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts).

    S. Ge, M. Chu, J. Choi, S. Louie, A. Kang, A. Vo, A. Peng, S. Jordan, M. Toyoda.

  • IgG Antibody Subclasses in Potential Renal Transplant Recipients with DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.

    A. Contreras, A. Casillas, L. Llorente, G. Lima, A. Arvizu, A. De Santiago, M. Vilatoba, J. Alberu, J. Arreola-Guerra.

  • IgM Immunotherapy Restores Immune Homeostasis in Type 1 Diabetes.

    P. Chhabra,1 C. Wilson,2 D. Moore,2 K. Brayman.1

  • IL-21R Antagonist Inhibits Differentiation of B Cells Towards Plasmablasts upon Alloantigen Stimulation.

    K. de Leur,1,2 F. Dor,4 M. Dieterich,1 L. van der Laan,2 R. Hendriks,3 C. Baan.1

  • IL-3 Contributes to Development of Basophil-Triggered Cardiac Allograft Fibrosis Development.

    G. Schiechl-Brachner,1 M. Rodriguez Gomez,1 K. Renner,1 S. Buchtler,1 K. Schmidbauer,1 D. Halbritter,1 S. Neumayer,1 Y. Talke,1 H. Bruehl,2 M. Mack.1

  • IL-33 Enhances the Ability of Dendritic Cells to Expand Human Regulatory T Cells.

    Y. Zhao,1 H. Zhang,1 L. Mathews,1 H. Turnquist,1,2 A. Thomson.1,2

  • IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection.

    H. Xu, T. Brennan, A. Kirk.

  • Imaging Cell Biology in Transplantation.

    T. Ueno,1 M. McGrath,1 M. Yeung,1 K. Jung,2 Y. Kihara,3 O. Konno,3 Y. Nakamura,3 H. Iwamoto,3 S. Yun,2 A. Chandraker.1

  • Immediate vs Delayed Initiation of CMV Prophylaxis…Safe and Cost Beneficial?

    L. Cotiguala, A. Carlson, C. Truax, B. Sirandas, I. Hall, L. Smith.

  • Immediate vs. Delayed Kidney Implantation Is Associated with Improved Kidney Graft Survival in Combined Liver-Kidney Transplantation.

    J. Halldorson, S. Rayhill.

  • Immune Activation and Rejection Risk in HIV-Positive Kidney Transplantation.

    S. Wisel, B. Shaw, L. Lee, K. Lee, C. Leung, P. Stock, Q. Tang.

  • Immune Monitoring-Guided Treatment of a Pediatric Patient with Sequential GvHD, Acute Rejection and CMV Infection Following Lung Transplantation.

    C. Falk,1 S. Nicolaus,2 M. Carsten,2 T. Igor,3 S. Wiebke,3 D. Kerstin,1 K. Jana,2 H. Gesine,2 H. Axel,3 W. Gregor.3

  • Immune Sensitization During Pregnancy Reduces Long-Term Benefit for Kidney Recipients of Offspring Living Donors.

    J. Cohen,1 L. Owei,2 D. Sawinski,1 P. Porrett.2

  • Immune Tolerance Monitoring in Renal Allograft Tolerance Induced by Transient Mixed Chimerism in Nonhuman Primates.

    K. Hotta, T. Oura, A. Dehnadi, K. Huh, M. Matsunami, G. Benichou, J. Madsen, A. Cosimi, T. Kawai.

  • Immunodominant Donor Specific Antibody Reduction with Proteasome Inhibitor Based Treatment: Clinical Variability and Implications for Long Term Graft Survival.

    A. Lichvar,1 A. Leino,1 S. Tremblay,1 A. Shields,2 B. Abu Jawdeh,1 B. Hardy,1 M. Anand,1 M. Cuffy,1 M. Cardi,1 R. Alloway,1 E. Woodle.1

  • Immunoregulatory Roles of CD137 Signaling in Graft-versus-Host Disease.

    H. Cho,1,2 J. Kim,1 B. Kwon,1,3 J. Lee,1,4 K. Park.1,4

  • Immunosuppressant Costs for Medicare Part D and Kidney Transplant Recipients Since the Introduction of Generic Formulations in an Incident Kidney Transplant Population.

    M. Helmuth,1 M. Turenne,1 J. Park,2 Q. Liu,1 M. Oguntimein,3 S. Dutcher,3 R. Balkrishnan,4 J. Zee,1 A. Smith,1 A. Leichtman.1

  • Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).

    B. Burrell,1 J. Bromberg,2 C. Hartono,3 A. Posselt,4 A. Naji,5 D. Kaufman,6 R. Redfield III,6 S. Kanaparthi,1 D. Ikle,7 K. Much,7 N. Bridges,8 L. Sun,1 A. Priore,8 M. DesMarais,1 K. Crisalli,9 S. Chandran,1 J. Markmann.9

  • Immunosuppression and Graft Rejection in Living-Related HLA-Identical Renal Transplantation.

    R. Ossman,1 M. Jamme,1 P. Galichon,1 A. Hertig,1 B. Moulin,2 C. Legendre,3 E. Morelon,4 J.-L. Taupin,5 L. Rostaing,6 E. Rondeau.1

  • Immunosuppressive Ability of NFkB Inhibitor: Withaferin A.

    M. Kanak,1 Y. Shindo,1 M. Levy,1,2 B. Naziruddin.3

  • Immunosuppressive Regimen Modification Approaches in BK Nephropathy – A Comparative Study.

    H. Ahmed, A. Roche-Recinos, C. Drachenberg, R. Ugarte, N. Costa, M. Mavanur, B. Thomas, A. Haririan.

  • Immunosuppressive Role of Pancreas Derived Mesenchymal Stem Cells.

    M. Kanak,1 F. Kunnathodi,2 M. Levy,1,3 M. Lawrence,2 B. Naziruddin.4

  • Immunosuppressive Therapy and Acute Rejection in Combined Heart and Kidney Transplantation.

    M. Gallo, J. Trivedi, D. Abramov, R. Vijayakrishnan, M. Slaughter.

  • Immunosuppressive Treatment Alters Gut Microbiota and Modified Gut Microbiota Affects Immune Status.

    Z. Zhang, Y. Xu, Q. Zhang, X. Hu.

  • Impact of a B-Cell Targeting Agent on Antibody Mediated Rejection and Graft' Survival in Liver Transplantation with Preformed DSAs.

    A. Del Bello,1 V. Dubois,2 J. Dumortier,3 N. Congy-Jolivet,4 N. Kamar.1

  • Impact of a Novel Prehabilitation Program in Kidney Transplant Candidates.

    M. McAdams DeMarco, H. Ying, A. Nastasi, D. Segev.

  • Impact of a Pharmacist-Led Vaccine Recommendation Program for Pediatric Kidney Transplant Candidates.

    C. Carthon,1 R. Hall,2 P. Maxwell,2 B. Crowther.2

  • Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.

    S. Jonchhe, J. Husson, J. Casale, R. Adekunle, P. Mathur, J. Gripshover, B. Ravichandran.

  • Impact of Antibiotic Treatment Duration for Symptomatic Lower Urinary Tract Infections in Kidney Transplant Recipients.

    S. Shaikh, S. Tischer, D. Kaul, A. Naik, M. Miceli, K. Gregg, N. Leja, T. Patel.

  • Impact of Antihypertensive (AHT) Choice and Advagraf® Dose on Immunologic Events in Renal Allografts 24 Months Post-Transplantation (Tx).

    D. Rush,1 S. Cockfield,2 S. Wilson,3 J. Howell,4 FKC-014 Study Group.

  • Impact of Antihypertensive (AHT) Choice and Advagraf® Dose on Interstitial Fibrosis/Tubular Atrophy (IF/TA) and IF/TA Progression in Renal Allografts 24 Months Post-Transplantation (Tx).

    S. Cockfield,1 D. Rush,2 S. Wilson,3 J. Howell,4 FKC-014 Study Group.

  • Impact of Bariatric Surgery on Risk of Organ Rejection Among Solid Organ Transplant Recipients.

    M. Soghikian, D. Gregory, J. Wilcox, A. Shetty, D. Ladner, L. VanWagner.

  • Impact of Belatacept Conversion on Kidney Transplant Function, Histology and Gene Expression.

    P. Sanghi,1 G. Gupta,1 D. Kumar,1 J. Reeve,2 M. Levy,1 A. Sharma,1 H. Fattah,1 P. Kimball,1 H. Massey,1 A. King,1 P. Halloran.2

  • Impact of Body Mass Index and Waist Circumference in Kidney Transplant Recipients.

    J.-E. Serre, M. Huet, I. Scwarc, V. Pernin, M. Le Quintrec, G. Mourad.

  • Impact of Caregiver on 30 Day Readmission After Lung Transplant.

    T. Coco, C. Keller, F. Alvarez, D. Erasmus, J. Mallea.

  • Impact of Cognitive Impairment on Kidney Transplantation Listing Between Sexes.

    C. Haugen,1 H. Ying,2 J. Garonzik Wang,1 M. McAdams-DeMarco,2 D. Segev.1,2

  • Impact of Cold Ischemia Time on Outcomes in Kidney Paired Donation (KPD).

    R. Redfield,1 D. Vock,2 R. Hayes,1 A. Matas.2

  • Impact of Complement Component 3 Single Nuclear Polymorphisms on Renal Transplant Recipients with Antibody-Mediated Rejection.

    Z. Wang, Z. Han, J. Tao, R. Tan, M. Gu.

  • Impact of Culture Expansion and Inflammatory Cytokine Challenge on DNA Methylation Profiles in MSC.

    S. de Witte,1 F. Peters,1 A. Merino,1 S. Korevaar,1 S. Elliman,3 P. Newsome,2 J. Meurs,1 K. Boer,1 C. Baan,1 M. Hoogduijn.1

  • Impact of Cytokine Gene Polymorphism on Clinical Outcome of Renal Transplantation.

    I. Pérez-Flores,1 J. Santiago,2 A. Moreno Dela Higuera,1 N. Calvo,1 B. Rodriguez-Cubillo,1 E. Urcelay,2 A. Shabaka,1 M. Calvo,1 A. Sanchez-Fructuoso.1

  • Impact of Dialysis During the Transplant Admission on Transplant and Post-Transplant Cost of Care.

    J. Tao,1 C. Horstman,1 W. Bannister,1 M. Schnitzler,2 F. Irwin,1 A. Bonagura,1 B. Laihinen.1

  • Impact of Donor Asystole in Intestine Transplant.

    J. Schroering, C. Kubal, R. Mangus.

  • Impact of Donor BK-Virus Replication on Posttransplant BKV Replication After Living-Donor Transplantation.

    J. Grellier, A. Del Bello, L. Esposito, A. Hebral, C. Mengelle, N. Kamar.

  • Impact of Donor Genotype on Recipient Tacrolimus Pharmacokinetics: The Liver Matters.

    S. Tremblay,1 T. Fukuda,2 T. Mizuno,2 E. Woodle,1 B. Abu Jawdeh,1 A. Govil,1 U. Christians,3 J. Klawitter,3 A. Vinks,2 R. Alloway.1

  • Impact of Early Allograft Dysfunction on Graft and Patient Outcomes After Liver Transplantation.

    Z. Guo, D. Zheng, X. He, G. Chen.

  • Impact of Early Pancreas Graft Failure on Patient and Kidney Graft Survival After Simultaneous Pancreas and Kidney Transplantation (SPK).

    A. Gruessner, M. Laftavi, V. Whittaker, Z. Acun, O. Pankowycz, R. Gruessner.

  • Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.

    C. Larsen,1 M. Alseiari,2 S. Chandran,2 F. Vincenti,2 D. Wojciechowski.1

  • Impact of Filgrastim Use on Maintenance Doses of Immunosuppressants and Clinical Outcomes in Renal Transplant Patients.

    C. Kane,1 K. Lang,2 T. Rendulic,1 M. Goetz,1 R. Evans,1 K. Trobaugh,1 J. Berger.1

  • Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis.

    J. Howell,1 R. Pollock,2 J. Schwartz.3

  • Impact of Induction Immunosuppression on the Recurrence of Primary IgA Nephropathy.

    K. Lee, C. Cho, N. Lee, K. Kim, S. Kim, J. Lee, J. Lee, H. Park, J. Park, S. Kim.

  • Impact of Inflammatory Bowel Disease on Survival and Risk of Retransplantation of Primary Sclerosing Cholangitis Patients Following Liver Transplantation: UNOS Data Analysis.

    O. Mousa,1 N. Patel,1 J. Corral,1 D. Lee,2 J. Nguyen,2 K. Croome,2 D. Harnois.2

  • Impact of Intensive Dosing of Mycophenolate on Pancreas Allograft Survival.

    J. Fose,1 K. Rolling,1 N. Menninga,1 G. Leverson,2 M. Jorgenson,1 J. Odorico,2 R. Robert.2

  • Impact of mTOR-Inhibition on Tolerance-Induction Following Heart Transplantation.

    M.-T. Dieterlen, K. Klaeske, J. Fischer, J. Hahn, K. Jawad, J. Garbade, F. Mohr, S. Lehmann.

  • Impact of NODAT on Post-Transplant Survival – An Analysis of UNOS Data.

    N. Sarabu, S. Deo, S. Park.

  • Impact of Non-Adherence in a Cohort of Kidney Transplant Recipients.

    M. Merino-López,1 C. Flores-Gama.2

  • Impact of Pancreas Transplant Failure in Quality of Life in Simultaneous Kidney Pancreas Transplantation.

    B. Alharbi, S. Aquil, H. Sharma, O. Ali, P. Luke, A. Sener.

  • Impact of Pancreatic Texture Assessment on Islet Isolation and Metabolic Outcome After TPIAT.

    G. Yoshimatsu,1 M. Khadka,1 M. Lawrence,1 B. Appakalai,2 B. Naziruddin.3

  • Impact of Pediatric Lung Transplant on Quality of Life Outcomes.

    T. Lazor,1 H. Grasemann,2,3,4 M. Solomon,2,3,4 S. Anthony.1,4,5,6

  • Impact of Peri-Transplant Viral Upper Respiratory Infection on Pediatric Liver Transplant Outcomes.

    J. Kohler,1 T. Miloh,1 K. Hosek,1 J. Goss,2 F. Munoz.1

  • Impact of Polymorphisms of UGT 1 A9 on the Prognosis of Renal Transplant Patients. Association with Digestive Tumors.

    N. Calvo, I. Perez-Flores, A. Shabaka, M. Moreno, B. Rodriguez-Cubillo, J. Delgado, M. Calvo, A. Sanchez-Fructuoso.

  • Impact of Post Kidney Donation Gout on eGFR and Kidney Stones.

    B. Sengupta, J. Menk, A. Matas.

  • Impact of Pre-Donation eGFR on Long-Term Post-Donation eGFR in Younger Living Kidney Donors.

    D. Vock, H. Ibrahim, A. Matas.

  • Impact of Pretransplant Panel-Reactive Antibody Level on Ocular Surface Stem Cell Survival and Visual Outcome.

    A. Govil,1 A. Cheung,2 E. Sarnicola,2 B. Genereux,2 E. Holland.2

  • Impact of Race on Selection of the Living Donor Candidate.

    D. Bohorquez, A. Thomasson, P. Porrett.

  • Impact of Ritonavir on Graft Function in Human Immunodeficiency Virus Infected Kidney Transplant Recipients.

    K. Roach, E. Meredith, M. Lyon.

  • Impact of Serum EDTA Treatment on Identification of Unacceptable Antigens for Kidney Transplant Candidates.

    J. Xin, N. Brown, R. Upchurch, J. Weidner, S. Marino.

  • Impact of Six-Month Surveillance Biopsies and Monitoring in Pediatric Renal Transplant Recipients.

    J. Lyons,1,2,3 D. Ranch,1,2 R. Hall,1,2,3 P. Maxwell,1,2,3 K. Hitchman,1,2 Y. Hirase,3 B. Crowther.1,2,3

  • Impact of STEEN vs Gelofusine as Perfusate During Normothermic Ex Vivo liver Perfusion on Outcome of Pig Liver Transplantation.

    I. Linares, D. Kollmann, J. Echeverri, M. Kaths, R. Rosales, C. Bruguera, M. Hamar, P. Urbanellis, S. Ganesh, N. Selzner, M. Selzner.

  • Impact of T-Cell Depletion on CMV-Specific Memory T and B Cell Homeostatic Proliferation After Kidney Transplantation.

    M. Jarque,2 S. Luque,2 E. Crespo,2 E. Melilli,1 J. Torras,1,2 J. Grinyó,1,2 O. Bestard.1,2

  • Impact of Timeliness of Assessment of Positive Cytomegalovirus Polymerase Chain Reaction Results in Abdominal Organ Transplant Recipients.

    K. Roach, H. Triemer, M. Hurtik, A. Mehta.

  • Impact of Type 2 Surgical Injuries in Postmortem Donor Kidneys on the Post-Transplant Outcomes When Compared to Mate Non-Injured Kidney from the Same Donor.

    M. Mujtaba,1 A. Gamilla-Crudo,1 K. Gugliuzza,2 O. Aleter,1 S. Shah,1 Y. Chapman,3 J. Reese,3 S. Masood,1 T. Taber.4

  • Impact of Type of Kidney (Living vs. Deceased) on Urinary Podocyte Excretion Rate in Renal Allografts.

    A. Naik, D. Luan, D. Cibrik, M. Samaniego, K. Woodside, M. Chowdhury, S. Wang, R. Wiggins.

  • Impact of Type of Recipient Diabetes on 1 and 3-Year Kidney Allograft and Patient Outcomes.

    S. Kim, F. Wu, D. Cibrik, Y. Li, A. Naik.

  • Impact of Visceral and Subcutaneous Adipose Tissue on Post Donation Renal Function in Living Kidney Donors.

    H. Lee,1 S. Kang,1 Y. Yoon,1 K. Huh,2 M. Kim,2 S. Kim,2 Y. Kim,2 W. Han.1

  • Impairment of Glucose Tolerance After Pediatric Kidney Transplant Is Associated with Worse Systemic Insulin Sensitivity Rather Than Fall in Insulin Secretion.

    D. Iwami, K. Hotta, H. Sasaki, T. Hirose, H. Higuchi, Y. Takada, N. Shinohara.

  • Implementing a New Specialist Requester Role to the United Kingdom to Address Consent Rates.

    S. Duncalf, M. Ryan.

  • Implementing a Successful DCD Heart Programme to the United Kingdom.

    M. Ryan, S. Duncalf.

  • Importance of Acquisition of Carbapenemase (KPC)-Producing Enterobacteriaceae in Solid Organ Transplant Recipients: A Single-Center Experience.

    S. Han,1 K. Lee,1 K.-A. Lee,1 H. Paik,2 J. Lee,2 M. Kim,3 D. Joo,3 J. Choi,3 S. Kim,3 Y. Kim.3

  • Importance of B Cell Antigen Specificity in Breg Dependent Tolerance.

    S. Kimura, L. Kojima, M. Aburawi, F. Fontan, J. Kim, K. Deng, H. Tector, K. Lee, H. Yeh, J. Markmann.

  • Importance of HLA-DR Expression in Pediatric Renal Transplant Biopsies.

    O. Moussa, S. Self, K. Twombley.

  • Improved Creatinine Immediately Post-LVAD Predicts Lower AKI Risk After Heart Transplant.

    A. Nanavati,1 Y. He,3 N. Moazami,2 S. Demirjian,1 B. Stephany.1

  • Improved Method to Obtain High Islet Mass from Severely Fibrotic Pancreatitis Pancreases Intended for Clinical Islet Auto-Transplantation.

    A. Balamurugan, G. Loganathan, W. Tucker, M. Dhanasekaran, S. Narayanan, A. Patel, S. Mokshagundam, S. Williams, M. Hughes.

  • Improved Mouse Renal Transplantation Model Simulating Clinical Antibody Mediated Rejection.

    D. Zhao, S. Li, T. Liao, X. Hua, F. Han, Z. Luo, X. Liu, Q. Sun.

  • Improved Outcome of Kidney Transplants by Donor Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes.

    O. Staeck,1 M. Niemann,4 F. Halleck,1 D. Khadzhynov,1 C. Schönemann,2 P. Reinke,1 E. Spierings,3 K. Budde,1 N. Lachmann.2

  • Improved Outcomes After Liver Transplantation from Controlled DCD Donors with Normothermic Regional Perfusion.

    G. Oniscu, F. Hunt, W. Herries, I. Currie, A. Sutherland, C. Beattie, E. Thomson.

  • Improved Preservation During Normothermic Ex-Vivo Liver Perfusion with Delta Opioid Agonist (D-Ala2, D-Leu5) Enkephalin (DADLE).

    E. Beal,1 J. Kim,1 D. Hayes Jr.,2 K. Washburn,1 B. Whitson,1 S. Black.1

  • Improvement in Inflammatory Response Follows Clearance of BKVN.

    E. Abuhelaiqa,1 S. Salvatore,2 J. Lee,1 J. Lee,1 T. Muthukumar,1 S. Seshan,2 D. Dadhania.1

  • Improvement of Cyclosporine A Dosing Strategy to Enhance Medication Adherence.

    M. Barten,1 E. Harmel,1 M. Goldmann,1 F. Wagner,1 H. Reichenspurner,1 M. Rybczynski.2

  • Improving Clinical Decisions for Kidney Transplant Recipients Through Online Medical Simulation.

    S. Gitzinger, E. Jackson, D. Blevins.

  • Improving Communication of SRTR Transplant Program Outcomes Evaluations Using a 5-Tier System.

    J. Snyder, A. Wey, N. Salkowski, A. Israni, B. Kasiske.

  • Improving Donor Screening for Cytomegalovirus (CMV): Is CMV IgG Avidity Better Than CMV IgM?

    H. Prince,1 M. Nowicki.1,2

  • Improving Liver Allocation Using Optimized Neighborhoods.

    S. Mehrotra, V. Kilambi.

  • Improving Vaccination Rates for Lung Transplant Candidates.

    M. Cortez,1 R. Bag,2 L. Potter.1

  • Improving Value by Standardizing the Use of IVIG Amongst Pediatric Solid Organ Transplant (SOT) Patients.

    J. Sawyer,1 J. Bucuvalas,2 L. Danziger-Isakov,3 J. Gossett,3 L. Burkhart,3 A. Lorts.3

  • In Clinic Systems to Address Adherence Barriers Decrease Late Allograft Rejection for Kidney Transplant Patients.

    D. Hooper, C. Varnell, Jr., K. Rich, D. Dahale, J. Huber, A. Pai, A. Modi.

  • In Depth Characterization of Ex Vivo Expanded Polyclonal Regulatory T Cells Used in a Phase I Clinical Trial Following Kidney Transplantation.

    J. Heinrichs,1 J. Mathew,1,2 I. Konieczna,1 J. He,1 X. Haung,1 A. LeFever,1 J. Leventhal.1

  • In Depth Characterization of the Innate Immune Response in Transplant Recipients with EBV Viremia.

    V. Ferreira, J. Batist, D. Kumar, S. Husain, A. Humar.

  • In Mid Wait Regions Shorter Height and Female Sex Confer Lower Probability of Liver Transplant (LT) Among Patients with Hepatocellular Carcinoma (HCC).

    M. Sarkar, M. Kohi, J. Dodge, J. Roberts, N. Mehta.

  • In the Modern Era, Cytomegalovirus Does Not Appear to Increase Intimal Thickening After Heart Transplantation.

    D. Leong, B. Azarbal, J. Patel, M. Kittleson, L. Czer, T. Aintablian, D. Chang, D. Geft, J. Kobashigawa.

  • In Vivo Administration of Plerixafor in Humans Mobilizes Bone Marrow Resident Plasma Cells That Demonstrate Apoptosis in Both Bone Marrow and Peripheral Blood.

    E. Woodle, S. Tremblay,1 C. Castro-Rojas,2 J. Driscoll,1 S. Knechtle,3 A. Shields,1 R. Alloway,1 D. Hildeman.2

  • Incidence and Clinical Outcomes of Mycobacterium tuberculosis Infections Following Renal Transplantation in Endemic Country.

    K. Jutivorakool, J. Vanichanan, G. Suwanpimolkul, Y. Avihingsanon, N. Townamchai.

  • Incidence and Clinical Outcomes of Active Tuberculosis in Transplant Recipients from a Low Prevalence Region.

    Y. Natori, A. Humar, S. Husain, D. Kumar.

  • Incidence and Outcomes of Immediate Post-Operative Dialysis in Liver Transplantation.

    S. Nagai, M. Safwan, K. Collins, M. Rizzari, A. Yoshida, M. Abouljoud.

  • Incidence and Outcomes of Re-Explorations in Living Donor Liver Transplantation.

    V. Varma, S. Sable, S. Kapoor, A. Chauhan, V. Kumaran.

  • Incidence and Risk Factors for Cervical Dysplasia Associated to Human Papillomavirus Infection in Women with Kidney Transplant.

    I. Parra-Avila, J. Alberu, L. Marino-Vazquez, L. Morales-Buenrostro, R. Rosado-Canto.

  • Incidence of De Novo Donor-Specific Antibodies Following Kidney Transplantation.

    B. Ho,1 H. Bhagat,2 E. Lee,2,3 K. Atiemo,1 A. Daud,1 R. Kang,1 S. Montag,1,4 L. Zhao,1,4 J. Schwartz,2 D. Ladner.1

  • Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.

    O. Marion,1 A. Del Bello,1 I. Ferrandiz,1 L. Esposito,1 N. Congy,2 A.-L. Hebral,1 N. Kamar.1

  • Incidence of Cytomegalovirus Infection Among Liver Transplant Recipients Maintained on a Cyclosporine vs. Tacrolimus-Based Immunosuppression Regimen.

    C. Burrelli, M. Bradley, S. Pouch, E. Elkhammas, H. Winters.

  • Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.

    N. Kamar, V. Hajj, I. Ferrandiz, E. Younes, L. Esposito, A. Hébral, A. Del Bello.

  • Incidence of Fungal and Viral Infections Following Rituximab Use in Kidney Transplant Recipients.

    L. Wong, M. Ison, C. Richardson, K. Cunningham, C. D'Agostino, C. Tseng, A. Shetty.

  • Incidence of Late-Onset Complications Related to Immunosuppressive Drugs Following Adult to Adult Living Donor Liver Transplantation, Especially Focusing on De Novo Malignancy.

    S. Mizuno, Y. Iizawa, H. Kato, Y. Murata, A. Tanemura, N. Kuriyama, M. Kishiwada, M. Usui, H. Sakurai, S. Isaji.

  • Incidence, Recurrence and Long Term Survival Post Chemotherapy in Renal Transplant Recipients with Post Transplant Lymphoproliferative Disorder: Single Center Study.

    R. Rathore, K. Tomlinson, H. Dukka, D. Farrugia, M. Lambie.

  • Incidental Hepatocellular Carcinoma in Explanted Livers: An Assessment After LIRADS Introduction.

    S. Garcia Aroz,1 D. Ludwig,2 K. Fowler,2 N. Vachharajani,1 M. Xu,1 Y. Lin,1 M. Doyle,1 W. Chapman.1

  • Increase in Post-Transplant Mortality Under KAS.

    A. Massie, J. Garonzik-Wang, D. Segev.

  • Increased Expression of Fibrillin-1 and Presence of Fibroblastic Reticular Cells in Treg-Rich Organized Lymphoid Structures (TOLS) of Accepted Kidney Allografts.

    A. Ayyar, C. Yang, D. Ndishabandi, R. White, P. Russell, J. Madsen, R. Colvin, A. Alessandrini.

  • Increased Gene Expression of TGF-β in Peripheral Blood Mononuclear Cells from Renal Transplant Patients with Polyomavirus BK Viremi.

    W. Yin.1,2

  • Increased Ischemic Inflammation Induces Recipient Endogenous Memory CD4 Cell-Graft Dendritic Cell Interactions to Provide Help for Activation of Endogenous Memory CD8 T Cells.

    H. Tsuda, T. Tanaka, C. Su, A. Valujskikh, R. Fairchild.

  • Increased Long-Term Mortality 20 years After Living Kidney Donation.

    G. Mjoen,1 S. Hallan,2 H. Holdaas.1

  • Increased Pro-Inflammatory and Decreased Interferon-Related Gene Expression in Older as Compared with Younger Kidney Transplant Recipients.

    J. Schaenman, O. Beiard, E. Liang, T. Sidwell, V. Groysberg, M. Rosetti, B. Abdalla, E. Lum, S. Bunnapradist, T. Pham, G. Dannovitch, J. Veale, H. Gritsch, A. Karlamangla, S. Cole, E. Reed.

  • Increased T Cell Exhaustion in Dialysis Patients.

    M. Bastiaansen, A. Uffing, L. Riella.

  • Increased Use of Donation After Cardiac Death Donors Increases Access to Transplantation without Adverse Effect on Outcomes.

    R. Helmick, J. Eason, S. Satapathy, J. Vanatta.

  • Increasing Liver Transplant Waitlist Dropout for Hepatocellular Carcinoma with Widening Geographical Disparities: Implications for Organ Allocation.

    N. Mehta, M. Sarkar, J. Dodge, R. Hirose, J. Roberts, F. Yao.

  • Increasing Living Donation by Implementing the Kidney Coach Program.

    D. LaPointe Rudow, S. Geatrakas, J. Armenti, A. Tomback, R. Shapiro.

  • Increasing Organ Supply in the US: A Systematic Review of Presumed Consent vs. Informed Consent (2006-2016).

    M. Ahmad,1 A. Hanna,1 A. Mohamed,1,2 R. Mhaskar,1 T. Jarmi,1,3 A. Schlindwein,4 C. Pley,4 I. Bahner.1

  • Increasing the Kidney Donor Pool by Expanding Limits on Body Mass Index and Age: A Single-Center Evaluation of Safety for Donors and Recipients.

    J. Tonascia, S. Yi.

  • Induced Pluripotent Stem Cell (iPS) Derived Schwann Cells to Enhance Functional Recovery Following Nerve Injury and Limb Allotransplantation.

    B. Kern,1 K. Sarhane,2 Z. Ibrahim,2 B. Mukherjee-Clavin,3 J. Budihardjo,2 C. Cashman,3 K. Krick,4 S. Schneeberger,1 W. Lee,2 H.-Q. Mao,4 G. Lee,3 G. Brandacher.2

  • Induction Immunotherapy in ECD and DGF Kidneys: Does ECD Equal Diminishing Induction Returns?

    M. Barrett, A. Smith, K. Woodside, R. Sung.

  • Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation.

    J. Lee, E. Liu, M. Aull, S. Kapur.

  • Induction of Delayed Renal Allograft Tolerance Using Only Clinically Available Reagents in Non-Human Primates.

    K. Hotta, T. Oura, A. Dehnadi, S. Boskovic, M. Matsunami, I. Rosales, N. Smith, R. Colvin, A. Cosimi, T. Kawai.

  • Induction of Durable Mixed Hematopoietic Chimerism and Immune Tolerance in Non-Human Primates.

    P. Alonso-Guallart,1 R. Duran-Struuck,1 J. Stern,1 S. Kofman,1 M. Danton,1 J. Zitsman,1 Y. Kato,1 E. Berglund,1 H. Sondermeijer,1 A. McMurchy,2 M. Levings,2 M. Sykes,1 A. Griesemer.1

  • Induction of Mixed Chimerism to Prolong Liver Allograft Survival in Cynomolgus Monkeys.

    E. Berglund, J. Stern, P. Alonso Guallart, S. Chaudhry, S. Kofman, M. Danton, J. Weiner, J. Lefkowitch, S. Baker, M. Martinez, Y. Kato, T. Kato, M. Sykes, A. Griesemer.

  • Induction of Proliferative Responses in B Cell and Plasma Cell Populations Following Proteasome Inhibitor Desensitization Treatment in Rhesus Macacques and Humans.

    J. Driscoll,1 S. Knechtle,2 J. Kwun,2 S. Tremblay,1 N. Salomonis,3 S. Potter,3 B. Aronow,3 M. Manook,2 R. Alloway,1 H. Singh,3 E. Woodle.1

  • Induction of Sensitization and Resistance to Transplant Tolerance by Allogeneic Pregnancy.

    A. Suah,1 J. Young,1 S. Hsu-Wei Khiew,1 Q. Wang,1 D. Yin,1 M.-L. Alegre,2 A. Chong.1

  • Induction of Tolerance to Renal Allografts in Non Human Primates by Concomitant Donor-Matched Vascularized Osteomyocutaneous Allotransplantation.

    F. Zhong,1 G. Zhao,2 Y. Wang,3 J. Jiang,3 Y. Wang,1 S. Ye,1 S. Tao,1 L. Cai,1 X. Wang,1 Q. Ye,1 G. Chen,2 X. Zheng.1

  • Induction Therapy in Low Risk Elderly Kidney Transplant Recipients: Donor Factors.

    F. Al Ammary, M. DeMarco, Q. Huang, E. King, S. Bay, A. Muzaale, A. Wiseman, D. Segev.

  • Induction Treatment with Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplant Recipients with Planned Early Steroid Withdrawal.

    S. Gabardi.

  • Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results.

    K. Korneffel, B. Gehring, G. Mitro, O. Aboderin, S. Makkar, W. Han, M. Rees, J. Ortiz.

  • Infectious Complications Following Hepatectomy for Pediatric Hepatoblastoma.

    S. Commander, M. Kueht, T.-A. Ha, A. Rana, J. Goss, S. Vasudevan.

  • Inferior 10-Year Graft and Patient Survival After End-to-Side Reconstruction for Two Renal Arteries in Living Donor Renal Transplantation.

    S. Yamanaga,1,2,3 A. Posselt,1 C. Freise,1 C. Niemann,1 A. Rosario,1 D. Fernandez,1 T. Kobayashi,3 A. Ahearn,4 M. Tavakol,1 S.-M. Kang.1

  • Inferior Graft and Patient Survival After Living Donor Renal Transplantation of Negatively Selected Right Kidneys.

    S. Yamanaga,1,2,3 A. Posselt,1 C. Freise,1 C. Niemann,1 A. Rosario,1 D. Fernandez,1 T. Kobayashi,3 A. Ahearn,4 M. Tavakol,1 S.-M. Kang.1

  • Inflammasome, Unfolded Protein Response, and T Cell Immunity in DAIH.

    A. Arterbery,1 M. Martinez,3 S. Lobritto,3 Y. Avitzur,2 U. Ekong.1

  • Inflammation, Impaired Energy Metabolism and Synthetic Failure Characterize the Liver Transcriptome of End-Stage Idiopathic Pediatric Acute Liver Failure (PALF).

    M. Ningappa,1 P. McKiernan,2 R. Squires,2 Q. Sun,1 B. Higgs,1 K. Soltys,1 G. Bond,1 C. Ashokkumar,1 G. Mazariegos,1 R. Sindhi.1

  • Inflammatory Conditions Dictate the Effect of MSC on B Cell Function.

    F. Luk,1 L. Carreras-Planella,2 S. Korevaar,1 S. de Witte,1 F. Borràs,2 M. Betjes,1 C. Baan,1 M. Hoogduijn,1 M. Franquesa.1,2

  • Inflammatory Cytokines Are Associated with Angiotensin II Type 1 Receptor Antibodies and Vascular Inflammation in Pediatric Renal Transplantation.

    M. Pearl,1 J. Grotts,1 M. Rossetti,1 Q. Zhang,1 M. Palma Diaz,1 D. Gjertson,1 P. Weng,1 E. Reed,1 E. Tsai.2

  • Influence of an Enhanced Recovery Protocol in Laparoscopic Living Donor Nephrectomy.

    A. Rege, D. Vikraman, K. Ravindra, T. Brennan, H. Leraas, D. Sudan.

  • Influence of Donor-Specific Antibodies on Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.

    J. Cruzado,1 H. Holdaas,1 P. Lopez,2 P. Bernhardt,2 G. Bader,2 F. Claas,1 W. Arns,1 M. van der Giet,1 J. de Fijter.1

  • Influence of Tacrolimus Metabolism Rate on Patients' Survival After Renal Transplantation.

    G. Thölking, J. Steinke, K. Schuette-Nuetgen, H. Pavenstädt, B. Suwelack, S. Reuter.

  • Influenza Viral Dynamics in a Large Cohort of Transplant Patients with Natural Influenza Infection.

    V. Ferreira,1 A. Humar,1 E. Cordero,2 E. Blumberg,3 A. Limaye,8 F. Silveira,5 L. Danziger-Isakov,6 M. Levi,7 J. Kalpoe,4 J. Englund,9 M. Multicenter Influenza Group, D. Kumar.1

  • Infusion of Polyclonal Tregs Modulates Subclinical Kidney Transplant Inflammation: Final Report of TASK Pilot Trial.

    S. Chandran, Q. Tang, M. Sarwal, Z. Laszik, A. Putnam, T. Sigdel, E. Tavares, J. Bluestone, F. Vincenti.

  • Inhibition of Bruton Tyrosine Kinase Blocks Sensitization in Response to Allogeneic Skin Transplantation and Prolong Skin Graft Survival.

    N. Datta, T. Palumbo, J. Kupiec-Weglinski, A. Zarrinpar.

  • Inhibition of Heat Shock Protein 90 Suppresses the Expression of MHC Class I Molecules, but Not MHC Class II Molecules, on Endothelial Cells in Allografts.

    T. Tanaka, T. Maehana, N. Masumori.

  • Inhibition of Liver Natural Killer Cells Activation Through Co-Transplantation of Pre-Activated Mesenchymal Stem Cells Contributes to Improvement of Islet Graft Survival.

    N. Ishida, K. Ishiyama, Y. Saeki, Y. Tanaka, H. Ohdan.

  • Inhibition of Memory T Cell Alloresponses by TIM-1+ B Cells.

    B. Gonzalez-Nolasco, H. Tector, J. Markmann, G. Benichou.

  • Inhibition of Multiple Nodes in the PI3K/Akt/mTOR Pathway Synergistically Suppresses Epstein-Barr Virus B Cell Lymphomas.

    A. Sang, G. Ivison, X. Qu, C. Esquivel, S. Krams, O. Martinez.

  • Initial Experince with Total Pancreatectomy-Islet Auto-Transplantation (TP-IAT) for Chronic Pancreatitis at the University of Louisville.

    M. Hughes,1 E. Davis,1 S. Mokshagundam,2 W. Tucker,1 G. Logananthan,1 S. Williams,3 B. Appakalai.1

  • iNKT Cell Activation Plus Veto Cell Transfer Yields Complete Chimerism in a Murine Sub-Lethal Bone Marrow Transplant Model.

    R. Ishii,1 T. Hirai,1 Y. Ishii,2 M. Okumi,1 K. Tanabe.1

  • Innate Lymphoid Cells Play a Critical Role in Regulating Allograft Homeostasis in Human Intestinal Transplantation.

    P. Cha, B. Houlihan, J. Kaiser, C. Cosentino, B. Monahan, A. Shukla, J. Hawksworth, C. Matsumoto, T. Fishbein, A. Kroemer.

  • Insulin Therapy in Pancreas Donors as a Predictor of Subsequent Transplant Outcome.

    I. Shapey,1 H. Khambalia,2 A. Summers,2 T. Augustine,2 M. Rutter,1 D. van Dellen.1

  • Integrated Magnetic-Electrochemical Exosome (iMEX) Technology to Detect Rejection in Kidney Transplant Recipients.

    J. Assaker, J. Park, S. Routray, S. Eskandari, H. Lee, J. Azzi.

  • Integration of Kidney-Exchange, (Un)Specified Living Donor Transplantation, ABO Incompatible and Desensitisation Programs in a Computerized Allocation Program: A Simulation.

    M. de Klerk,1 J. Kal,1 S. Middel,1 J. van de Wetering,1 M. Kho,1 M. Betjes,1 W. Zuidema,1 D. Roelen,3 K. Glorie,2 J. Roodnat.1

  • Integrative Analysis of ExomeSeq and Gene Expression Data for Identification of Novel Variants Associated with Antibody-Mediated Rejection in Kidney Transplant.

    S. Pineda,1,2 T. Sigdel,2 A. Jackson,3 M. Sirota,1,2 M. Sarwal.2

  • Intended and Unexpected Impact of the New Kidney Allocation System on a Large Volume Transplant Program.

    A. de Mattos, M. Alnimri, L.-X. Chen, J. Sageshima, C. Santhanakrishnan, R. Perez.

  • Intensive Care Unit Enhanced Recovery Pathway for Liver Transplant Recipients: A Prospective, Observational Study.

    C. Kensinger, A. King, S. Karp, P. Pandharipande, K. Wright, L. Weavind.

  • Interruption of RAAS in Hypertensive Proteinuric Kidney Donors.

    O. Sanchez,1 L. Ferrara,1 D. Berglund,1 A. Matas,2 R. Foley,1 H. Ibrahim.1

  • Intraabdominal Infections (IAI) and Bloodstream Infections in Small Intestinal and Multivisceral Transplants (IMVTX).

    A. Spence,1 S. Fogleman,1 G. Raffaele,2 C. Matsumoto,2 P. Kumar,1 R. Biswas,1 T. Fishbein,2 J. Timpone.1

  • Intraomental Non-Purified Islet Transplantation Isolated from DCD Donor Pancreas.

    S. Wang, G. Pei, Y. Liu, Z. Wang, B. Zhang, Y. Xie, J. Wang, Z. Shen.

  • Intraoperative Fluid Management During Pediatric Kidney Transplantation with Less Than 15kg Body Weight Using Transesophageal Echocardiaography as Hemodynamic Parameter.

    Y. Watarai,1 S. Narumi,1 R. Kimura,1 K. Hatazoe,1 M. Okada,1 K. Futamura,1 T. Yamamoto,1 T. Hiramitsu,1 M. Tsujita,1 N. Goto,1 Y. Goto.2

  • Intravoxel Incoherent Motion MRI Is an Effective Way to Monitor Acute Allograft Rejection in Rat Models.

    S. Zeng, X. Hu.

  • IP-10 Monoclonal Antibody Treatment Suppresses Inflammatory Components of IBMIR and Improves Pancreatic Islet Graft Function.

    G. Yoshimatsu,1 C. Chang,1 C. Darden,1 P. Saravanan,1 B. Naziruddin,2 M. Lawrence.1

  • Is “Death with a Functioning Graft (DWF)” Really Death with Function? Data from the Long-Term Deterioration of Kidney Allograft Function (DeKAF) Study.

    R. Gaston,1 A. Fieberg,2 L. Hunsicker,3 D. Rush,4 R. Leduc,2 J. Connett,2 A. Matas,2 DeKaf Investigators.

  • Is Deceased Donor Kidney Transplantation (DDTX) Justified in Patients with More Than 10 Years of Pre-TX Dialysis Exposure?

    C. Rose, J. Gill, J. Lesage, Y. Joffres, J. Gill.

  • Is It Safe to Use Older Donor Liver Grafts for Older Recipients?

    M. Safwan, K. Collins, K. Takahashi, M. Rizzari, A. Yoshida, M. Abouljoud, S. Nagai.

  • Is Lung Allocation Score Associated with Waitlist and Post-Transplant Survival?

    H. Maredia, M. Bowring, A. Massie, S. Oyetunji, C. Merlo, R. Higgins, D. Segev, E. Bush.

  • Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.

    G. Gu, H. Hang, Q. Xia.

  • Is Peri-Transplant Plasmapheresis Effective in the Prevention of Recurrence of FSGS?

    P. Verghese, M. Rheault, S. Chinnakotla, S. Jackson, A. Matas, B. Chavers.

  • Is Reluctance to Accept Younger Kidney Donors Justified?

    H. Ibrahim,1 D. Berglund,1 S. Jackson,2 A. Matas.1

  • Is the Current Heart Allocation System Just and Fair for Blood Type O Recipients? – A Propensity-Matched Analysis of 34353 Patients in the UNOS Registry.

    M. Ando, K. Takeda, P. Kurlansky, M. Wright, C. Lee, J. Han, A. Garan, V. Topkara, M. Yuzefpolskaya, P. Colombo, M. Farr, Y. Naka, H. Takayama.

  • Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes?

    A. Zhang,1 Y. Sun,2 K. McCurry,3 M. Budev.3

  • Is There a [bdquo]Weekend Effect“ in Kidney Transplantation? – A Single Center Study.

    K. Schütte-Nütgen, G. Thölking, H. Pavenstädt, B. Suwelack, S. Reuter.

  • Is There a Role for Electronic Health Service in of Therapeutic Drug Monitoring of Immunosuppression?

    M. Barten,1 I. Hausladen,2 F. Mohr, J. Garbade.

  • Is There an Association Between Number of Outpatient Primary Care Visits (OPV) and Outcomes in Kidney Transplantation (KTP)?

    A. O'Shea, R. Kalil.

  • Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect.

    J. Lee,1 J. Lee,1 S. Song,1 S.-K. Kwon,1 D. Kim,1 J. Lee,2 M. Kim,1 G. Choi,1 J. Choi,1 D. Han,1 S. Kim,1 D. Joo.1

  • Is Thymic Function Determining Rejection Onset in Heart Transplantation?

    A. Sannier,1,2 R. Dorent,1,3 M. Le Borgne,1 N. Stroumza,1 J. Senemaud,1 L. Louedec,1 F. Andreata,1 A. Gaston,1 C. Deschildre,1 P. Nataf,1,3 A. Couvelard,2 G. Caligiuri,1 A. Nicoletti.1

  • Ischemia Reperfusion Injury (IRI) Causes Local Release of Free Heme Which Aggravates Inflammation and Contributes to Delayed Graft Function.

    F. Gueler,1 R. Chen,1 A. Thorenz,1 K. Madyaningrana,2 J. Bräsen,3 H. Haller,1 S. Immenschuh,3 V. Vijayan.3

  • Ischemia-Reperfusion Injury-Induced Innate Immune Signaling in Human Orthotopic Liver Transplantation.

    R. Sosa,1 A. Zarrinpar,2 M. Rossetti,1 C. Lassman,1 B. Naini,1 N. Datta,2 R. Busuttil,2 D. Gjertson,1 J. Kupiec-Weglinski,1,2 E. Reed.1

  • Islet Rejection in Autoimmune NOD Mouse Recipients: Implications for Stem Cell Therapies.

    R. Gill,1 M. Coulombe,1 T. Kupfer,1 K. Beard,1 A. Burrack.2

  • Isoflurane Precondition Alleviated Murine Liver Ischemia and Reperfusion Injury by Restoring AMPK/mTOR-Mediated Autophagy.

    Z. Rao,1 H. Zhou,2 X. Pan,1 M. Gao,1 Z. Wang,1 J. Sun,1 C. Liu,1 Z. Ding.1

  • Isolated Angiotensin II Receptor Type I Antibodies (AT1R) Are Not Associated with Active Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients.

    J. Choi, M. Haas, X. Zhang, O. Aubert, H. Pizzo, E. Kamil, K. Irene, S. Jordan, D. Puliyanda.

  • It's Never too Early to Test: Frequent Anti-A2 Titer Monitoring in Blood Group B Patients is Necessary.

    S. Radomski, S. Rosen-Bronson, B. Diedrich, A. Langeberg, D. Li, M. Awwad, M. Grafals, M. Cooper, A. Gilbert.

  • IVIG + Rituximab as Desensitization Agents to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly Hla Sensitized (HS) Awaiting Deceased Donor Kidney Transplantation.

    R. Najjar, E. Huang, A. Vo, J. Cho, S. Louis, A. Hang, A. Peng, S. Jordan.

  • IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts).

    S. Ge, B.-H. Shin, J. Mirocha, D. Thomas, M. Chu, E. Rodriguez, C. Chao, A. Petrosyan, O. Galera, A. Vo, J. Choi, A. Peng, J. Kahwaji, S. Jordan, M. Toyoda.

Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2023 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences